About
Low-dose psychedelics for non-psychiatric conditions
Areas of Focus
Categories
Psychedelic
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
4
As Collaborator
2
Total Enrollment
1,005
By Phase
PHASE2: 3EARLY_PHASE1: 1PHASE3: 2
By Status
RECRUITING: 2TERMINATED: 2COMPLETED: 2
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06969170Collaborator
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
PHASE2Recruiting
50 participants
Started: May 6, 2025 · Completed: Aug 30, 2026
NCT05227742Collaborator
Exploratory Study of Low Dose Psilocybin
EARLY_PHASE1Recruiting
60 participants
Started: Aug 15, 2023 · Completed: Dec 31, 2025
NCT00751842Lead Sponsor
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
PHASE3Terminated
331 participants
Started: Sep 30, 2008 · Completed: Jul 31, 2012
NCT00723411Lead Sponsor
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)
PHASE3Terminated
334 participants
Started: Jul 31, 2008 · Completed: Aug 31, 2011
NCT00435981Lead Sponsor
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
PHASE2Completed
70 participants
Started: Jan 31, 2005 · Completed: Dec 31, 2007
Locations (1)
Headquarters
Toronto, ON, Canada
Map
Loading map...